腹腔内贝伐珠单抗联合热化疗对老年卵巢癌患者血转化生长因子β1和巨噬细胞移动抑制因子水平的影响  

The effect of abdominal Bevacizumab combined with hyperthermia chemotherapy on serum transforming growth factor beta 1 and migration-inhibitory factor levels in elderly patients with ovarian cancer

作　　者：刘海燕[1] 官燕 孙颖[1] 李大鹏 Liu Haiyan;Guan Yan;Sun Ying;Li Dapeng

机构地区：[1]泰山医学院附属医院肿瘤科,泰安271000 [2]山东大学附属山东省肿瘤医院妇四科,济南250117

出　　处：《中华老年医学杂志》2018年第4期434-436,共3页Chinese Journal of Geriatrics

摘　　要：目的探讨腹腔内贝伐珠单抗联合热化疗对老年卵巢癌患者血转化生长因子β1（TGF-β1）、巨噬细胞移动抑制因子（MIF）水平的影响。方法选取2011年12月至2014年12月我院确诊治疗的老年卵巢癌患者100例，依据治疗方法分为联合组和热疗组，每组50例，热疗组给予腹腔内热化疗治疗，联合组在此基础上加用贝伐珠单抗治疗，统计患者治疗疗效、不良反应、治疗前后血TGF-β1、MIF水平及2年生存情况。结果治疗有效率联合组（23/50，64.0%）高于热疗组（22/50，44.0%）（χ2＝4.026，P＝0.04）；联合组2年生存（60.0%），高于热疗组（40.0%）（χ2＝4.000，P＝0.038）；热疗组治疗前后血TGF-β1[（346.15±35.15）ng/L和（201.46±23.75）ng/L]、MIF[（46.32±5.16）μg/L和（13.48±2.45）μg/L]，联合组治疗前后血TGF-β1[（342.26±35.01）ng/L和（167.52±20.26）ng/L]、MIF[（46.97±5.24）μg/L和（4.87±1.02）μg/L]，两组治疗后血TGF-β1、MIF水平低于治疗前，但联合组降低更显著（t＝7.69和22.94，均P〈0.01）；两组不良反应发生率基本相同，（P〉0.05）。结论腹腔内贝伐珠单抗联合热化疗可有效降低老年卵巢癌患者血TGF-β1、MIF水平，有利于提高近远期疗效，且具有良好的安全性。Objective To investigate the effect of abdominal Bevacizumab combined with hyperthermia chemotherapy on serum transforming growth factor beta1 （TGF-β1） and macrophage migration-inhibitory factor （MIF） levels in elderly patients with ovarian cancer.MethodsA hundred elderly patients diagnosed with ovarian cancer from December 2011 to December 2014 at our hospital were recruited.Participants were assigned into a joint therapy group （n=50） and a thermal therapy group （n=50） according to the received treatment.Both groups were given the abdominal hyperthermia chemotherapy treatment, while the joint therapy group was additionally given Bevacizumab treatment.The effectiveness of treatment, adverse reactions, pre-and post-treatment serum TGF-β1 and MIF levels, and the 2-year survival situation in all participants were collected and analyzed.ResultsThe therapeutic response rate and 2-year survival rate in the joint therapy group （64.0% and 60.0%） were significantly higher than those in the thermal therapy group （44.0% and 40.0%） （both P〈0.05）. There were statistically significant differences between pre-and post-treatment levels of serum TGF-β1 [（346.15±35.15） ng/L vs.（201.46±23.75） ng/L] and MIF [（46.32±5.16）μg/L vs.（13.48±2.45）μg/L] in the thermal therapy group, and of serum TGF-β1 [（342.26±35.01） ng/L vs.（167.52±20.26） ng/L] and MIF [（46.97±5.24）μg/L vs.（4.87±1.02）μg/L] in the joint therapy group, with greater reductions observed in the joint therapy group （P〈0.05）. No significant difference in the incidence of adverse reactions was found between the two groups （P〉0.05）. ConclusionsAbdominal Bevacizumab combined with hyperthermia chemotherapy can effectively decrease the levels of serum TGF-β1 and MIF in elderly patients with ovarian cancer and achieve improved short-term and long-term effectiveness with good safety.

关 键 词：卵巢癌 转化生长因子β1 巨噬细胞游走抑制因子 贝伐珠单抗 热化疗 

分 类 号：R737.31[医药卫生—肿瘤]